Loading...
Dear Readers,
The past year brought exciting advances and insights into both the management and biologic underpinnings of various malignant and classic hematologic disorders. The expanding use of immunotherapy and targeted therapies has positively impacted outcomes in a variety of disorders. Importantly, understanding the molecular subset of patients most likely to benefit, or not, from new therapies is a critical goal of tailored therapeutic interventions. Finally, symptom management remains foundational as clinicians deal with these disorders, and having new tools to palliate symptoms is always welcomed.
The top NEJM Journal Watch Oncology and Hematology stories for 2023 are:
Efanesoctocog Alfa Shows Promise for Severe Hemophilia A Therapy
Sublobar Resection Is Now Standard of Care for Some Patients with Early-Stage NSCLC
Rucaparib vs. Standard-of-Care Therapies in Metastatic, Castration-Resistant Prostate Cancer
PET-Adapted Treatment of Hodgkin Lymphoma
Bevacizumab Added to FTD-TPI in Third-Line Therapy for Metastatic Colorectal Cancer
Frontline Venetoclax for Chronic Lymphocytic Leukemia
Capivasertib for Advanced ER+/HER2− Breast Cancer
Preoperative Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer
Perioperative Nivolumab and Chemotherapy in Stage III NSCLC
Safely Omitting Breast Radiation Therapy
Olanzapine Improves Weight Gain in Patients with Advanced Cancer on Chemotherapy